Cargando…

Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients

BACKGROUND: Infantile hemangiomas (IHs) are the most frequently occurring pediatric lesions. Oral propranolol has been shown to be safe and effective in infants with IHs. Side effects such as sleep disturbances have been associated with propranolol. Atenolol is a hydrophilic, selective β1-blocker an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ze-Liang, Liu, Chao, Wang, Qi-Zhang, Wu, Hai-Wei, Zheng, Jia-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867894/
https://www.ncbi.nlm.nih.gov/pubmed/33569418
http://dx.doi.org/10.21037/atm-20-5359
_version_ 1783648367978479616
author Zhao, Ze-Liang
Liu, Chao
Wang, Qi-Zhang
Wu, Hai-Wei
Zheng, Jia-Wei
author_facet Zhao, Ze-Liang
Liu, Chao
Wang, Qi-Zhang
Wu, Hai-Wei
Zheng, Jia-Wei
author_sort Zhao, Ze-Liang
collection PubMed
description BACKGROUND: Infantile hemangiomas (IHs) are the most frequently occurring pediatric lesions. Oral propranolol has been shown to be safe and effective in infants with IHs. Side effects such as sleep disturbances have been associated with propranolol. Atenolol is a hydrophilic, selective β1-blocker and therefore may be not associated with side effects attributable to β2-adrenergic receptor blockade and lipophilicity. However, the efficacy of atenolol in the treatment of IHs is poorly understood. The aim of this study was to evaluate the efficacy of atenolol in the treatment of proliferating IHs in a clinical cohort including 133 consecutive patients. METHODS: In this study, we enrolled 133 patients diagnosed as proliferating IHs from the routine clinical and referral practices of the authors. The procedures followed were in accordance with the ethical standards of the Institute Review Board of Shanghai Ninth People’s Hospital and Helsinki Declaration. Clinical characteristics, including demographic data and clinical morphology, were collated. Responses to oral atenolol therapy were graded as: excellent, good, fair and poor. According to the reaction to atenolol treatment, additional medications or therapy were used for IH patients to achieve satisfactory clinical results. RESULTS: In this study, 128 (96.2%) of 133 IH patients responded to oral atenolol, and the response rate (RR) was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest RR. The mean time of treatment was 4.9 months. Forty-one patients who exhibited residual hyperpigmentation or telangiectasia were further treated with timolol maleate cream (n=32) or pulsed dye laser (n=9). All the 41 patients showed positive response. No life-threatening complications were noted during and after oral atenolol. Only 4 (3.0%) of 133 patients developed minor complications including diarrhea. No agitation and bronchospasm were noted in our study. CONCLUSIONS: This study demonstrated that atenolol was effective in the treatment of IHs. Compared to propranolol, atenolol seems to have a similar effect on IHs. Furthermore, atenolol seems to be less frequently associated with potentially life-threatening side effects.
format Online
Article
Text
id pubmed-7867894
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78678942021-02-09 Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients Zhao, Ze-Liang Liu, Chao Wang, Qi-Zhang Wu, Hai-Wei Zheng, Jia-Wei Ann Transl Med Original Article BACKGROUND: Infantile hemangiomas (IHs) are the most frequently occurring pediatric lesions. Oral propranolol has been shown to be safe and effective in infants with IHs. Side effects such as sleep disturbances have been associated with propranolol. Atenolol is a hydrophilic, selective β1-blocker and therefore may be not associated with side effects attributable to β2-adrenergic receptor blockade and lipophilicity. However, the efficacy of atenolol in the treatment of IHs is poorly understood. The aim of this study was to evaluate the efficacy of atenolol in the treatment of proliferating IHs in a clinical cohort including 133 consecutive patients. METHODS: In this study, we enrolled 133 patients diagnosed as proliferating IHs from the routine clinical and referral practices of the authors. The procedures followed were in accordance with the ethical standards of the Institute Review Board of Shanghai Ninth People’s Hospital and Helsinki Declaration. Clinical characteristics, including demographic data and clinical morphology, were collated. Responses to oral atenolol therapy were graded as: excellent, good, fair and poor. According to the reaction to atenolol treatment, additional medications or therapy were used for IH patients to achieve satisfactory clinical results. RESULTS: In this study, 128 (96.2%) of 133 IH patients responded to oral atenolol, and the response rate (RR) was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest RR. The mean time of treatment was 4.9 months. Forty-one patients who exhibited residual hyperpigmentation or telangiectasia were further treated with timolol maleate cream (n=32) or pulsed dye laser (n=9). All the 41 patients showed positive response. No life-threatening complications were noted during and after oral atenolol. Only 4 (3.0%) of 133 patients developed minor complications including diarrhea. No agitation and bronchospasm were noted in our study. CONCLUSIONS: This study demonstrated that atenolol was effective in the treatment of IHs. Compared to propranolol, atenolol seems to have a similar effect on IHs. Furthermore, atenolol seems to be less frequently associated with potentially life-threatening side effects. AME Publishing Company 2021-01 /pmc/articles/PMC7867894/ /pubmed/33569418 http://dx.doi.org/10.21037/atm-20-5359 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhao, Ze-Liang
Liu, Chao
Wang, Qi-Zhang
Wu, Hai-Wei
Zheng, Jia-Wei
Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title_full Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title_fullStr Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title_full_unstemmed Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title_short Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
title_sort oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867894/
https://www.ncbi.nlm.nih.gov/pubmed/33569418
http://dx.doi.org/10.21037/atm-20-5359
work_keys_str_mv AT zhaozeliang oralatenololtreatmentforinfantilehemangiomasclinicalanalysisof133consecutivepatients
AT liuchao oralatenololtreatmentforinfantilehemangiomasclinicalanalysisof133consecutivepatients
AT wangqizhang oralatenololtreatmentforinfantilehemangiomasclinicalanalysisof133consecutivepatients
AT wuhaiwei oralatenololtreatmentforinfantilehemangiomasclinicalanalysisof133consecutivepatients
AT zhengjiawei oralatenololtreatmentforinfantilehemangiomasclinicalanalysisof133consecutivepatients